Free Trial
NASDAQ:LEXX

Lexaria Bioscience (LEXX) Stock Price, News & Analysis

Lexaria Bioscience logo
$1.32 -0.37 (-22.13%)
As of 12:21 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About Lexaria Bioscience Stock (NASDAQ:LEXX)

Key Stats

Today's Range
$1.23
$1.45
50-Day Range
$1.21
$1.82
52-Week Range
$1.15
$4.44
Volume
367,491 shs
Average Volume
169,886 shs
Market Capitalization
$23.11 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$7.00
Consensus Rating
Buy

Company Overview

Lexaria Bioscience Corp. operates as a biotechnology company. It develops and out-licenses its patented drug delivery technology, DehydraTECH, which combines lipophilic molecules or active pharmaceutical ingredients with specific long-chain fatty acids and carrier compounds that improve the way they enter the bloodstream, increasing their effectiveness and allowing for lower overall dosing while promoting healthier oral ingestion methods. The company's DehydraTECH is used with a range of active molecules encompassing fat-soluble vitamins, pain medications, hormones, PDE5 inhibitors, antivirals, oral nicotine and its analogs, and cannabinoids. Its DehydraTECH technology evaluates therapeutic indications, including hypertension, heart disease, and diabetes; and is suitable for a variety of product formats, such as pharmaceuticals, nutraceuticals, over the counter, and consumer packaged goods. Lexaria Bioscience Corp. was incorporated in 2004 and is headquartered in Kelowna, Canada.

Lexaria Bioscience Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
40th Percentile Overall Score

LEXX MarketRank™: 

Lexaria Bioscience scored higher than 40% of companies evaluated by MarketBeat, and ranked 435th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Lexaria Bioscience has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Lexaria Bioscience has received no research coverage in the past 90 days.

  • Read more about Lexaria Bioscience's stock forecast and price target.
  • Earnings Growth

    Earnings for Lexaria Bioscience are expected to grow in the coming year, from ($0.59) to ($0.46) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Lexaria Bioscience is -2.60, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Lexaria Bioscience is -2.60, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Lexaria Bioscience has a P/B Ratio of 2.74. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Lexaria Bioscience's valuation and earnings.
  • Percentage of Shares Shorted

    4.18% of the float of Lexaria Bioscience has been sold short.
  • Short Interest Ratio / Days to Cover

    Lexaria Bioscience has a short interest ratio ("days to cover") of 4.5.
  • Change versus previous month

    Short interest in Lexaria Bioscience has recently increased by 30.20%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Lexaria Bioscience does not currently pay a dividend.

  • Dividend Growth

    Lexaria Bioscience does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    4.18% of the float of Lexaria Bioscience has been sold short.
  • Short Interest Ratio / Days to Cover

    Lexaria Bioscience has a short interest ratio ("days to cover") of 4.5.
  • Change versus previous month

    Short interest in Lexaria Bioscience has recently increased by 30.20%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Lexaria Bioscience has a news sentiment score of 0.38. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.74 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 2 news articles for Lexaria Bioscience this week, compared to 1 article on an average week.
  • Insider Buying vs. Insider Selling

    In the past three months, Lexaria Bioscience insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    26.40% of the stock of Lexaria Bioscience is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    Only 13.06% of the stock of Lexaria Bioscience is held by institutions.

  • Read more about Lexaria Bioscience's insider trading history.
Receive LEXX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Lexaria Bioscience and its competitors with MarketBeat's FREE daily newsletter.

LEXX Stock News Headlines

Lexaria provides GLP-1 update following industry developments
Now I look stupid. Real stupid...
I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again.
Lexaria Bioscience begins dosing for GLP-1 study #5
See More Headlines

LEXX Stock Analysis - Frequently Asked Questions

Lexaria Bioscience's stock was trading at $2.10 at the beginning of the year. Since then, LEXX shares have decreased by 37.3% and is now trading at $1.3160.
View the best growth stocks for 2025 here
.

Lexaria Bioscience Corp. (NASDAQ:LEXX) released its quarterly earnings data on Monday, April, 14th. The company reported ($0.15) earnings per share for the quarter, topping analysts' consensus estimates of ($0.16) by $0.01. The company had revenue of $0.17 million for the quarter, compared to analyst estimates of $0.14 million. Lexaria Bioscience had a negative trailing twelve-month return on equity of 88.88% and a negative net margin of 1,473.04%.

Lexaria Bioscience's top institutional shareholders include Byrne Asset Management LLC (0.16%). Insiders that own company stock include Richard Christopher, Catherine C Turkel and Vanessa Carle.
View institutional ownership trends
.

Shares of LEXX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Lexaria Bioscience investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Advanced Micro Devices (AMD), Adobe (ADBE), Arista Networks (ANET) and Builders FirstSource (BLDR).

Company Calendar

Last Earnings
4/14/2025
Today
4/25/2025
Next Earnings (Estimated)
7/11/2025
Fiscal Year End
8/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:LEXX
Fax
N/A
Employees
7
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$7.00
High Stock Price Target
$7.00
Low Stock Price Target
$7.00
Potential Upside/Downside
+314.2%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-5,800,000.00
Net Margins
-1,473.04%
Pretax Margin
-1,475.05%

Debt

Sales & Book Value

Annual Sales
$525,923.00
Price / Cash Flow
N/A
Book Value
$0.48 per share
Price / Book
3.52

Miscellaneous

Free Float
12,919,000
Market Cap
$29.67 million
Optionable
Not Optionable
Beta
0.86
Beginner's Guide To Retirement Stocks Cover

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

This page (NASDAQ:LEXX) was last updated on 4/25/2025 by MarketBeat.com Staff
From Our Partners